Organon & Co. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
Organon & Co. (OGN) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-07-31
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-06-30 was $0.00.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-03-31 was -$1.00M.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was -$21.00M, a 1150.00% decline year-over-year.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$21.00M, a 1150.00% decline from fiscal 2024.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was $2.00M, a 92.00% decline from fiscal 2023.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $25.00M.
- Organon & Co. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$23.00M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-31 | -$1.00M 10-Q · filed 2026-07-31 | -$22.00M derived: sum of 3 quarters · filed 2026-07-31 | -$22.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-04 | -$22.00M derived: sum of 2 quarters · filed 2026-05-04 | -$22.00M derived: sum of 3 quarters · filed 2026-05-04 | -$22.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | -$21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$21.00M derived: sum of 2 quarters · filed 2026-02-24 | -$21.00M derived: sum of 3 quarters · filed 2026-07-31 | -$21.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-07-31 | $0.00 10-Q · filed 2025-11-10 | $2.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-31 | $0.00 10-Q · filed 2026-07-31 | $2.00M derived: sum of 3 quarters · filed 2026-07-31 | $3.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $2.00M derived: sum of 2 quarters · filed 2026-05-04 | $3.00M derived: sum of 3 quarters · filed 2026-05-04 | $3.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.00M derived: sum of 2 quarters · filed 2026-02-24 | $3.00M derived: sum of 3 quarters · filed 2026-02-24 | $2.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-10 | $1.00M derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $24.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | -$1.00M 10-Q · filed 2025-08-06 | $23.00M derived: sum of 3 quarters · filed 2026-02-24 | $23.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$1.00M 10-Q · filed 2025-05-02 | $23.00M derived: sum of 2 quarters · filed 2026-02-24 | $23.00M derived: sum of 3 quarters · filed 2026-02-24 | $24.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.00M derived: sum of 2 quarters · filed 2026-02-24 | $25.00M derived: sum of 3 quarters · filed 2026-02-24 | $25.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-01 | $1.00M derived: sum of 2 quarters · filed 2024-11-01 | $1.00M 10-Q · filed 2024-11-01 | -$22.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $1.00M 10-Q · filed 2024-08-07 | $1.00M 10-Q · filed 2024-08-07 | -$22.00M derived: sum of 3 quarters · filed 2025-11-10 | -$22.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-03 | -$23.00M derived: sum of 2 quarters · filed 2025-11-10 | -$23.00M derived: sum of 3 quarters · filed 2025-11-10 | -$24.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | -$23.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | -$23.00M derived: sum of 2 quarters · filed 2025-11-10 | -$24.00M derived: sum of 3 quarters · filed 2025-11-10 | -$23.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-03 | -$1.00M derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | -$19.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$1.00M 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | -$19.00M derived: sum of 3 quarters · filed 2024-02-26 | -$16.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-05 | -$18.00M derived: sum of 2 quarters · filed 2024-02-26 | -$15.00M derived: sum of 3 quarters · filed 2024-02-26 | -$9.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$16.00M derived: sum of 2 quarters · filed 2024-02-26 | -$10.00M derived: sum of 3 quarters · filed 2024-02-26 | -$8.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $3.00M 10-Q · filed 2022-11-04 | $9.00M derived: sum of 2 quarters · filed 2022-11-04 | $11.00M 10-Q · filed 2022-11-04 | $169.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $6.00M 10-Q · filed 2022-08-05 | $8.00M 10-Q · filed 2022-08-05 | $166.00M derived: sum of 3 quarters · filed 2023-02-27 | $162.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-06 | $160.00M derived: sum of 2 quarters · filed 2023-02-27 | $156.00M derived: sum of 3 quarters · filed 2023-02-27 | $153.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $158.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $154.00M derived: sum of 2 quarters · filed 2023-02-27 | $151.00M derived: sum of 3 quarters · filed 2023-02-27 | $143.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$4.00M 10-Q · filed 2021-11-12 | -$7.00M derived: sum of 2 quarters · filed 2021-11-12 | -$15.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$3.00M 10-Q · filed 2021-08-16 | -$11.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$8.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $60.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |